Statement on combined hormonal contraceptives containing third- or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolism
Statement on combined hormonal contraceptives containing third- or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolism
复制标题
DOI：
10.1136/jfprhc-2013-100624
复制
发表时间：
2013-07-01
影响因子：
--
通讯作者：
Bitzer, Johannes
中科院分区：
文献类型：
--
作者：
Bitzer, Johannes
围绕所谓第三代复方激素避孕药（CHCs）的争议（含孕二烯酮或去氧孕烯）和第四代（含有屈螺酮，DRSP）已经达到了一个高度情绪化的政治层面，所有那些专业负责妇女健康的人都参与其中：国家卫生当局、制药公司、专业组织、开处方者，传媒及公众（即社区健康中心的现有或潜在使用者）。最初的科学争议现在已经导致了一场公共卫生争议，最终导致法国当局决定从市场上撤回含有乙炔基孕酮（EE）和醋酸环丙孕酮（CPA）的组合。这一措施的潜在影响，即对所有社区卫生中心失去信心，可能相当严重。
The controversy around the combined hormonal contraceptives (CHCs) of the so-called third (containing gestodene or desogestrel) and fourth generation (containing drospirenone, DRSP) has reached a highly emotional political dimension in which all those who are professionally responsible for women’s health are involved: the national health authorities, the pharmaceutical companies, the professional organisations, the prescribers, the media and the public (ie the current or potential users of CHCs). The–initially scientific–controversy has now led to a public health dispute that culminated in the decision of the French authorities to withdraw the combination containing ethinylestradiol (EE) and cyproterone acetate (CPA) from the market. The potential impact of this measure, namely the loss of confidence in all CHCs, could be quite serious.